Moderna’s $2.25B Patent Deal: Arbutus, Genevant, and Section 1498

On March 3, 2026, Moderna agreed to pay up to $2.25 billion to settle patent infringement claims brought by Arbutus Biopharma and Genevant Sciences over the lipid nanoparticle technology used in the Spikevax COVID-19 vaccine. The Moderna $2.25 billion patent settlement is split into two pieces: a fixed $950 million upfront payment due by July 8, 2026, and up to $1.3 billion in contingent money that Moderna will owe only if a pending federal appeal goes against it. In return, Moderna received a worldwide non-exclusive license to use the technology in its infectious-disease vaccines and consented to a court judgment that four of the Arbutus and Genevant patents were both valid and infringed.¹²

Who Arbutus and Genevant Are

Arbutus Biopharma is a Canadian biopharmaceutical company, formerly known as Tekmira Pharmaceuticals until a mid-2015 name change, that developed a lipid nanoparticle delivery platform for RNA-based therapies.³ In April 2018, Arbutus and Roivant Sciences formed Genevant Sciences as a jointly owned 50/50 subsidiary. Arbutus contributed its LNP and ligand conjugate delivery technology, and Genevant became the exclusive licensee of that intellectual property for uses outside hepatitis B.⁴ Under their arrangement, Arbutus keeps 20 percent of settlement proceeds after litigation costs.²

What the Lawsuit Was About

Lipid nanoparticles are tiny fat-based capsules that protect fragile mRNA molecules and carry them into human cells. Without a delivery system like this, mRNA vaccines such as Spikevax cannot work. Arbutus scientists developed a formulation using a specific blend of four lipid types: a cationic lipid, a phospholipid, cholesterol, and a PEG-conjugated lipid. The same platform was used in Alnylam’s patisiran, the first FDA-approved RNA therapy.⁵⁶

Arbutus and Genevant filed suit in the U.S. District Court for the District of Delaware on February 28, 2022, alleging that Spikevax used their patented LNP recipe without authorization.⁷ The complaint originally named six U.S. patents, and the dispute later grew to include Moderna’s RSV vaccine, mRESVIA.⁸ Moderna denied infringement and maintained it had developed its own proprietary LNP technology independently.⁵

How the $2.25 Billion Breaks Down

The settlement, announced March 3, 2026, resolves all LNP-related patent litigation between the parties worldwide. It has two payment components.

The upfront payment is $950 million. It is fixed and noncontingent, and Moderna must pay it by July 8, 2026.²

The contingent payment can reach $1.3 billion. It becomes owed only if the Federal Circuit (or a final, non-appealable judgment) affirms the district court’s ruling that a federal government-contractor defense does not shield Moderna from the vast majority of the infringement claims. If the appellate court finds the defense applies to only some vaccine doses, the $1.3 billion is prorated accordingly. And if Moderna initially loses the appeal but later prevails through en banc review, Supreme Court action, or remand, Arbutus and Genevant must refund the contingent amount with interest.²⁹

What Moderna Gets and What It Concedes

In exchange for the payments, Genevant granted Moderna a fully paid-up, royalty-free, irrevocable, non-exclusive worldwide license to its LNP delivery technology for SM-102-based mRNA vaccines against infectious diseases. The license covers Spikevax, the next-generation vaccine mNEXSPIKE, and mRESVIA, and comes with a covenant not to sue on certain additional patents and products.²

On the other side, Moderna consented to the court entering a judgment of infringement and “no invalidity” on the four patents at the center of the case: U.S. Patent Nos. 8,492,359; 9,364,435; 9,504,651; and 11,141,378.⁹

Why the Deal Happened When It Did

The settlement landed less than a week before a scheduled March 9, 2026 trial. Two pretrial rulings by Judge Joshua D. Wolson pushed both sides toward a deal.

On February 2, 2026, Judge Wolson addressed Moderna’s most consequential defense: Section 1498, a federal statute that can redirect patent claims against government contractors to the U.S. Court of Federal Claims. Moderna argued that because it produced Spikevax under Operation Warp Speed, the patent claims should be treated as claims against the government. The court largely rejected that argument, holding that “for the Government” requires the patented product to be used for the direct benefit of the government itself. Only roughly 1.25 percent of doses, those provided to government employees, qualified. That kept more than $8.2 billion in Moderna’s government vaccine sales at issue.¹⁰

The same ruling gave Moderna a win on prosecution history estoppel. Because Arbutus had removed the word “about” from its claimed lipid ranges during patent prosecution, the court barred Arbutus from asserting infringement under the doctrine of equivalents, forcing it to prove infringement under a stricter literal standard at trial.¹⁰

Then, on February 17, 2026, Judge Wolson granted summary judgment for Arbutus on both obviousness and derivation, finding that Moderna was blocked by IPR estoppel and had not shown prior conception of the technology. Only one invalidity defense survived for trial: enablement.¹¹

The combined effect was billions in exposure still on the table for Moderna and a harder infringement path for Arbutus. Days later, they settled.

The Section 1498 Appeal That Controls the $1.3 Billion

The biggest open question is whether Moderna will ever pay the $1.3 billion contingent piece. Moderna has publicly expressed “confidence in its appeal to the U.S. Court of Appeals for the Federal Circuit” and has said it does not consider a loss on the Section 1498 issue to be probable.⁹ As of mid-2026, available reporting does not confirm that Moderna has formally docketed the appeal, and no briefing schedule or oral argument date has been publicly disclosed. Under the settlement, Moderna has 90 days after an adverse appellate ruling to pay.

What Arbutus and Roivant Receive

Because Arbutus keeps 20 percent of settlement proceeds after litigation costs, the company said it expects to receive approximately $178.7 million from the July 2026 upfront payment.¹² Arbutus management said in May 2026 that it was evaluating a return of capital to shareholders in the third quarter of 2026, without announcing a specific distribution amount.¹³ Roivant Sciences, Genevant’s other parent, approved a $1 billion share repurchase program after the deal was announced.¹⁴

What This Settlement Does Not End

The deal closes the Moderna dispute over LNP technology but leaves adjacent litigation running. Arbutus and Genevant remain in active U.S. litigation against Pfizer and BioNTech over the Comirnaty vaccine, a case that received a favorable claim-construction ruling in September 2025.¹ Acuitas Therapeutics filed a declaratory judgment action in 2023 seeking rulings that ten Arbutus and Genevant patents are invalid or not infringed.¹⁵ And Bayer, through its Monsanto subsidiaries, sued Moderna, Pfizer, and Johnson & Johnson in January 2026 over a separate patent covering mRNA-stability technology; that case was in the motion-to-dismiss phase as of June 2026.¹⁶ Separately, Alnylam Pharmaceuticals lost its lipid-patent case against Moderna in June 2025, when the Federal Circuit affirmed a non-infringement ruling and held that a key claim term did not cover the lipid used in Spikevax.¹⁷

1
Genevant Sciences. Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
2
Stock Titan. Arbutus Biopharma Corp Reports Material Event
3
Arbutus Biopharma. Arbutus Biopharma Finalizes Corporate Name Change
4
Arbutus Biopharma. Arbutus Biopharma and Roivant Sciences Joint Venture Agreement
5
Chemistry World. Moderna Sued Over Covid-19 Vaccine Related Patents
6
SEC. Arbutus Biopharma Corporation Form 10-K
7
CourtListener. Arbutus Biopharma Corporation v. Moderna, Inc.
8
Fierce Pharma. Moderna Fronts $950M, More Potentially in Line, to Settle Yearslong Covid Patent Litigation
9
IPWatchdog. Moderna Settles With Genevant and Arbutus, Ending LNP Patent Dispute
10
IPWatchdog. Judge Wolson Issues Key Summary Judgment Ruling on Eve of Trial in Arbutus v. Moderna
11
IPWatchdog. Delaware Court Narrows Moderna’s Invalidity Defenses Ahead of Arbutus LNP Patent Trial
12
Arbutus Biopharma. Arbutus Reports First Quarter 2026 Financial Results
13
Yahoo Finance. Arbutus Biopharma Among Best Performing Healthcare Stocks
14
Roivant Sciences. Roivant Announces Genevant Sciences and Arbutus Biopharma’s $2.25 Billion Global Settlement
15
Goodwin Law. Acuitas Seeks Declaratory Judgment Against Arbutus and Genevant
16
CourtListener. Bayer CropScience LLC v. Moderna, Inc.
17
U.S. Court of Appeals for the Federal Circuit. Alnylam Pharmaceuticals, Inc. v. Moderna, Inc., No. 2023-2357